Attachment B

In the Claims:

1-17 (cancelled)

18. (new) A compound of the general Formula (I):



(I)

wherein

- R_1, R_2, R_3 and R_4, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C_1-C_6) alkyl group, a linear or branched (C_1-C_6) alkoxy group, a linear or branched (C_1-C_6) carboxylate group,
- R_5 represents a hydrogen atom or a linear or branched (C_1-C_6) alkyl group,
- m is an integer between 1 and 2, and
- n is an integer between 8 and 20.

19. (new) The compound according to Claim 18, wherein n is an integer between 8 and 16.

20. (new) The compound according to Claim 19, wherein n is an integer equal to 8, 10, 12, 13, 14 or 16.

21. (new) The compound according to Claim 18, wherein the compound is a compound selected from TFA12, TFA14, TFA15, TFA16 and TFA18.

22. (new) The compound according to Claim 18, wherein R_5 represents a hydrogen atom or a methyl group.

23. (new) The compound according to Claim 18, wherein the carbon atom bearing the substituent R_5 has the *R* or *S* configuration or is a mixture.

24. (new) The compound of Formula (I) according to Claim 18, wherein at least one, preferably only one, of the substituents R_1, R_2, R_3 and R_4 on the aromatic ring, represents a hydroxyl, alkoxy or carboxylate group.

25. (new) The compound of Formula (I) according to Claim 18, wherein the linear or branched C_1-C_6 alkyl group is the methyl, ethyl, isopropyl or tert-butyl radical.

26. (new) The compound of Formula (I) according to Claim 18, wherein the linear or branched (C_1-C_6) alkoxy group is the methoxy, ethoxy, isopropoxy or *tert.*-butoxy group.

27. (new) A pharmaceutical composition comprising at least one compound according to Claim 18, in association with a pharmaceutically acceptable carrier.

28. (new) A pharmaceutical composition comprising at least one compound having the following general Formula (I) as the active principle:



(I)

wherein

- R_1, R_2, R_3 and R_4, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C_1-C_6) alkyl group, a linear or branched (C_1-C_6) alkoxy group, a linear or branched (C_1-C_6) carboxylate group,

- R_5 represents a hydrogen atom or a linear or branched (C_1-C_6) alkyl group,

- m is an integer between 1 and 2, and

- n is an integer between 8 and 20,

stimulating the modulation of the specification of the neural stem cells and/or the differentiation of cells that are precursors of oligodendrocytes in oligodendroglial cells and/or repressing the activation of microglial cells and/or the activation of astrocytes and/or reactive gliosis, in association with a pharmaceutically acceptable carrier.

29. (new) Use of at least one compound having the following general Formula (I):



(I)

wherein

- R_1, R_2, R_3 and R_4, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C_1-C_6) alkyl group, a linear or branched (C_1-C_6) alkoxy group, a linear or branched (C_1-C_6) carboxylate group,

- R_5 represents a hydrogen atom or a linear or branched (C_1-C_6) alkyl group,

- m is an integer between 1 and 2, and

- n is an integer between 8 and 20,

in the preparation of a pharmaceutical composition for the prevention or treatment of diseases of the nervous system altering the oligodendrocytes or

the other cells of the nervous system and/or the inflammation of the nervous system.

30. (new) The method of preparing a pharmaceutical compound comprising at least one compound having the following general Formula (I):



(I)

wherein

- R_1, R_2, R_3 and R_4, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C_1-C_6) alkyl group, a linear or branched (C_1-C_6) alkoxy group, a linear or branched (C_1-C_6) carboxylate group,
- R_5 represents a hydrogen atom or a linear or branched (C_1-C_6) alkyl group,
- m is an integer between 1 and 2, and
- n is an integer between 8 and 20

where in said pharmaceutical composition is for the prevention or the treatment of degenerative neuropathies.

31. (new) The method according to Claim 30, wherein the pharmaceutical composition is intended for the prevention or the treatment of demyelinising or dysmyelinising diseases.

32. (new) The method according to Claim 30, wherein the pharmaceutical composition prevents or treats a member selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease, cerebral vascular accidents and any other damaging attacks to the nervous system.

33. (new) Method of at least one compound according to Claim 18 for the preparation of a pharmaceutical composition intended to modulate, *in vivo* or *in vitro*, the cellular specification of the neural stem cells, to favour the differentiation and then the survival of the neurones and glial cells in differentiation, to favour the differentiation of precursor cells of oligodendrocytes in mature oligodendrocytes, and/or to reduce the activation of the microglia and/or the activation of the astrocytes and/or the reactive gliosis.

34. (new) A process for preparing a compound of Formula (I) according to Claim 18, wherein said process includes the reaction steps of the following scheme:



wherein:

- R_1, R_2, R_3 and R_4, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C_1-C_6) alkyl group, a linear or branched (C_1-C_6) alkoxy group, a linear or branched (C_1-C_6) carboxylate group,

- R_5 represents a hydrogen atom or a linear or branched (C_1-C_6) alkyl group,

- n is an integer between 8 and 16 and
- R_6 represents a benzyl group or a *tert.*-butyldimethylsilyl group.